X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (884) 884
index medicus (576) 576
male (514) 514
female (455) 455
psychiatry (444) 444
sustained-release bupropion (409) 409
adult (377) 377
pharmacology & pharmacy (359) 359
middle aged (283) 283
double-blind (262) 262
neurosciences (258) 258
smoking cessation (219) 219
bupropion (201) 201
treatment outcome (196) 196
smoking cessation - methods (192) 192
depression (182) 182
bupropion - therapeutic use (171) 171
clinical neurology (165) 165
sustained attention (162) 162
antidepressants (161) 161
receptor partial agonist (161) 161
sustained-release (155) 155
smoking (151) 151
animals (144) 144
placebo (135) 135
adolescent (134) 134
varenicline (129) 129
major depressive disorder (126) 126
smoking-cessation (125) 125
nicotine (124) 124
drug therapy (120) 120
aged (118) 118
smoking cessation programs (118) 118
placebo-controlled trial (115) 115
efficacy (113) 113
care and treatment (111) 111
bipolar disorder (109) 109
double-blind method (109) 109
article (108) 108
randomized controlled-trial (108) 108
medicine, general & internal (107) 107
pharmacotherapy (106) 106
analysis (105) 105
major depression (103) 103
antidepressive agents - therapeutic use (97) 97
neuropsychological tests (93) 93
nicotine replacement therapy (93) 93
schizophrenia (93) 93
depressive disorder, major - drug therapy (91) 91
research (90) 90
antidepressive agents, second-generation - therapeutic use (87) 87
cigarette-smoking (87) 87
young adult (86) 86
risk factors (85) 85
health aspects (84) 84
medicine & public health (79) 79
substance abuse (79) 79
delayed-action preparations (78) 78
smokers (78) 78
antidepressant (76) 76
bupropion - adverse effects (75) 75
clinical trials (74) 74
bupropion sustained-release (73) 73
cognition (72) 72
tobacco (71) 71
sustained virological response (70) 70
therapy (69) 69
attention (68) 68
cessation (68) 68
safety (66) 66
psychology, clinical (65) 65
studies (65) 65
nicotinic agonists - therapeutic use (64) 64
depression, mental (63) 63
randomized controlled trials as topic (63) 63
drug therapy, combination (62) 62
internal medicine (62) 62
mental disorders (62) 62
dose-response relationship, drug (61) 61
serotonin reuptake inhibitors (60) 60
tobacco use disorder - drug therapy (60) 60
hepatitis c, chronic - drug therapy (59) 59
psychiatric status rating scales (59) 59
smoking prevention (59) 59
antiviral agents - therapeutic use (58) 58
drugs (57) 57
nicotine - administration & dosage (56) 56
bipolar disorder - psychology (55) 55
hepatitis c (54) 54
mental depression (54) 54
pharmacology/toxicology (54) 54
psychology (54) 54
quality-of-life (54) 54
comorbidity (53) 53
nicotine - therapeutic use (53) 53
rats (53) 53
serotonin uptake inhibitors - therapeutic use (53) 53
time factors (52) 52
dependence (51) 51
pharmacokinetics (51) 51
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Expert Opinion on Therapeutic Targets, ISSN 1472-8222, 11/2016, Volume 20, Issue 11, pp. 1389 - 1392
The N-methyl-D-aspartate (NMDA) receptor antagonist ketamine is one of the most attractive antidepressants since this drug causes rapid-onset and sustained... 
Antidepressant | hydroxynorketamine | ketamine | (R)-ketamine | esketamine | DEPRESSION | R-KETAMINE | PHARMACOLOGY & PHARMACY | SUSTAINED ANTIDEPRESSANT | RAPID-ONSET | Receptors, N-Methyl-D-Aspartate - antagonists & inhibitors | Depression | Ketamine - analogs & derivatives | Depressive Disorder | Antidepressive Agents | Humans
Journal Article
Psychopharmacology, ISSN 0033-3158, 10/2016, Volume 233, Issue 19-20, pp. 3647 - 3657
The N-methyl-d-aspartate (NMDA) receptor antagonists, including R-ketamine and rapastinel (formerly GLYX-13), show rapid antidepressant effects in animal... 
Antidepressant | R-ketamine | Rapastinel | Brain-derived neurotrophic factor | Synaptogenesis | PATH | FUNCTIONAL PARTIAL AGONIST | BDNF | PSYCHIATRY | D-ASPARTATE ANTAGONIST | NEUROSCIENCES | TRIAL | GLYX-13 | PHARMACOLOGY & PHARMACY | SUSTAINED ANTIDEPRESSANT | RAPID-ONSET | Nucleus Accumbens - metabolism | Disks Large Homolog 4 Protein - metabolism | Disks Large Homolog 4 Protein - drug effects | Male | Hippocampus - drug effects | Brain - metabolism | Brain-Derived Neurotrophic Factor - drug effects | Depression - drug therapy | CA3 Region, Hippocampal - drug effects | Prefrontal Cortex - drug effects | Dentate Gyrus - drug effects | Stress, Psychological - metabolism | CA3 Region, Hippocampal - metabolism | Antidepressive Agents - pharmacology | Brain-Derived Neurotrophic Factor - metabolism | Swimming | Receptor, trkB - drug effects | Receptors, AMPA - metabolism | Disease Models, Animal | Dentate Gyrus - metabolism | Excitatory Amino Acid Antagonists - pharmacology | Hindlimb Suspension | Brain - drug effects | Hippocampus - metabolism | Animals | Prefrontal Cortex - metabolism | Mice | Ketamine - pharmacology | Nucleus Accumbens - drug effects | Oligopeptides - pharmacology | Receptor, trkB - metabolism | Receptors, AMPA - drug effects | Ketamine | Antidepressants | Depression, Mental | Comparative analysis | Drug therapy | Stress (Psychology) | Health aspects | Psychopharmacology | Stress | Original Investigation
Journal Article
Biological Psychiatry, ISSN 0006-3223, 03/2019, Volume 85, Issue 6, pp. e25 - e27
Journal Article
Scientific Reports, ISSN 2045-2322, 12/2018, Volume 8, Issue 1, p. 4007
Since the metabolism of (R, S)-ketamine to (2R, 6R)-hydroxynorketamine (HNK) is reported to be essential for ketamine's antidepressant effects, there is an... 
LC-MS/MS | NMDA RECEPTORS | BIPOLAR DEPRESSION | R-KETAMINE | MULTIDISCIPLINARY SCIENCES | KETAMINE METABOLITE | SUSTAINED ANTIDEPRESSANT | MECHANISMS | D-ASPARTATE ANTAGONIST | N-DEMETHYLATION | RAPID-ONSET
Journal Article
Neuropharmacology, ISSN 0028-3908, 03/2019, Volume 146, pp. 149 - 153
Recent studies have indicated that sub-anesthetic dose of ketamine exerts rapid antidepressant effects. Upregulation of... 
Antidepressant | NLRP3 | Ketamine | AMPA | LPS | DEPRESSION | CYTOKINES | CASPASE-1 | BEHAVIOR | INVOLVEMENT | SOCIAL DEFEAT STRESS | MECHANISMS | NEUROSCIENCES | INHIBITION | PHARMACOLOGY & PHARMACY | SUSTAINED ANTIDEPRESSANT | MICE
Journal Article
Journal of Psychiatry and Neuroscience, ISSN 1180-4882, 2017, Volume 42, Issue 4, pp. 222 - 229
Journal Article
Current Neuropharmacology, ISSN 1570-159X, 2018, Volume 16, Issue 4, pp. 426 - 437
Journal Article